Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThINKK Adoptive Immunotherapy in Children Post-HSCT for Leukemia or Neuroblastoma
NCT07518654Phase 1Not yet recruiting
- Start
- May 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and neuroblastoma. Primary endpoints: Incidence and severity of treatment-emergent adverse events and serious adverse events, Incidence of dose-limiting toxicities and 1 more. Planned start May 2026; status: not yet recruiting.
02
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)neuroblastoma
Beyond the preview
Go deeper on NCT07518654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07518654.